Minireview: Animal model of schizophrenia from the perspective of behavioral pharmacology: Effect of treatment on cognitive functions

Schizophrenia is a debilitating mental disorder characterized by positive, negative and cognitive symptoms. Whereas positive symptoms are satisfactorily addressed by current antipsychotic treatment, negative and cognitive symptomatic treatment remains largely ineffective. This review investigates the treatment efficacy regarding cognitive symptoms and evaluates the contribution of different monoamine receptor systems involved in schizophrenia pathophysiology to cognition. In the review, we included preclinical studies assessing the effect of different treatments on cognition in pre-pulse inhibition and two spatial cognitive tests. While pre-pulse inhibition investigates pre-attentive processes operating outside of conscious awareness, the spatial tasks require continuous attention and active engagement in task solving for a successful outcome. The schizophrenia-like phenotype was attained by acute or subchronic administration of non-competitive NMDA receptor antagonist MK-801.

Automated summary

Schizophrenia is a severe mental disorder with positive, negative, and cognitive symptoms, for which current antipsychotic treatment is only effective for positive symptoms. This review evaluates the treatment efficacy for cognitive symptoms and the contribution of different monoamine receptor systems in schizophrenia pathophysiology to cognition, focusing on pre-pulse inhibition and spatial cognitive tasks in preclinical studies.